BRIEF—Former Novartis oncology head becomes EpimAb CMO

Shanghai’s EpimAb Biotherapeutics has appointed Bin Peng as chief medical officer.

Dr Peng is the former global head of oncology at Swiss giant Novartis, and was a major contributor to the worldwide clinical development of Gleevec (imatinib).

Chief executive Chengbin Wu said: “We are excited to have recruited Dr Peng to our management team as we move our first candidate EMB01, a bispecific antibody with unique properties, into the clinic.”

Dr Peng said: “I am delighted to join EpimAb at this transformative stage of its development. The company’s antibody platform technology is providing many new pipeline opportunities and I look forward to contributing to its future growth and continued success.”